Aktienanalyse zu Kenvue Inc (KVUE)KVUEKenvue Inc

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM). It operates in the Consumer Non-Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Kenvue Inc is a good buy right now as it is currently priced at $18.91, which is below the analyst price targets of $19 from both UBS and Barclays. The stock has shown a strong upward trend with a 5-day change of +6.84% and a year-to-date change of +9.18%. However, the main risk is its high P/E ratio of 49.26, which indicates that it may be overvalued relative to its earnings.

1 analysts cover KVUE: 0 rate it Buy, 0 Hold and 1 Sell. The average price target is 18.86.